Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brachial Artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    111 result(s) found for: Brachial Artery. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-004012-78 Sponsor Protocol Number: TCW-05/02 Start Date*: 2005-12-16
    Sponsor Name:Medical University of Graz
    Full Title: Effects of acarbose on endothelial function, platelet activity, insulin sensitivity and glucose control in subjects with coronary artery disease and new onset type-II diabetes.
    Medical condition: Patients with angiographically verified coronary artery disease and newly detected type-2 diabetes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-006141-16 Sponsor Protocol Number: OXBIO Start Date*: 2006-10-13
    Sponsor Name:University of Oxford
    Full Title: A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects with Coronary Artery Disease
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004376-35 Sponsor Protocol Number: ISSBRILO176 Start Date*: 2014-01-14
    Sponsor Name:Hellenic Cardiovascular Research Society
    Full Title: A Single Center, Phase II, Assessor-Blinded, RaNdomized, Active Controlled, Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections...
    Medical condition: Coronary Artery Disease (with an indication for coronary angiography)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004779-35 Sponsor Protocol Number: CL2-16257-096 Start Date*: 2012-04-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid) on top of beta-blockers, on central aortic blood pressure. Randomized, cross-over, double blind, mul...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000156-16 Sponsor Protocol Number: A509 1043 Start Date*: 2004-09-14
    Sponsor Name:Pfizer AB
    Full Title: Phase 3 multi center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, ...
    Medical condition: Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    10011078
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002796-28 Sponsor Protocol Number: CEASESTIFFNESS Start Date*: 2016-04-12
    Sponsor Name:University Medical Center Groningen (UMCG)
    Full Title: The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers.
    Medical condition: Systemic sclerosis (SSc) is characterized by skin fibrosis and visceral disease, mainly of the lungs, kidneys and the heart, accompanied by microvascular damage ultimately leading to digital ischem...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003652-35 Sponsor Protocol Number: 300 Start Date*: 2006-02-02
    Sponsor Name:Barnsley Hospital NHS Foundation Trust
    Full Title: A randomised, double blind, placebo controlled study to assess the effect of testosterone treatment on arterial stiffness in patients with type 2 diabetes, peripheral vascular disease and hypogonad...
    Medical condition: Male Hypogonadism
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002383-34 Sponsor Protocol Number: TMC114HIV3017 Start Date*: 2008-10-09
    Sponsor Name:JANSSEN-CILAG
    Full Title: A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002799-42 Sponsor Protocol Number: CAPstatin2013 Start Date*: 2014-03-27
    Sponsor Name:Dipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma
    Full Title: Statins in the prevention of myocardial damage in pneumonia
    Medical condition: Patients hospitalized with community-acquired pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016600-23 Sponsor Protocol Number: 05102009 Start Date*: 2010-07-09
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: A double blind, randomised, placebo controlled trial to study the clinical effectiveness of Angiotensin Converting Enzyme (ACE) inhibitors, ramipril,in patients with intermittent claudication
    Medical condition: Intermittent Claudication
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019760-36 Sponsor Protocol Number: T05018-2004 Start Date*: 2010-11-22
    Sponsor Name:Grifols Therapeutics, Incorporated
    Full Title: A Phase 2, Randomized, Open-label (with Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Comp...
    Medical condition: acute peripheral arterial occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10057525 Peripheral artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-001427-12 Sponsor Protocol Number: CACZ885M2201 Start Date*: 2013-06-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability and effects on arterial structure and function of ACZ885 in patients with intermittent claudication
    Medical condition: Peripheral Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10003611 Atherosclerosis of arteries of the extremities, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001053-44 Sponsor Protocol Number: Carotis-Rivaroxaban_CEUS_001 Start Date*: 2020-09-30
    Sponsor Name:Rigshospitalet, Department of Vascular Surgery
    Full Title: Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS)
    Medical condition: Patients with - Stable peripheral artery disease and - Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10075495 Internal carotid artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004164-11 Sponsor Protocol Number: DAPA-BP Start Date*: 2015-11-19
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Effect of dapagliflozin on flow-mediated dilation and blood pressure (DAPA-BP): a phase III, randomized, open-label, parallel group study in hypertensive patients with controlled type 2 diabetes
    Medical condition: Arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003615-70 Sponsor Protocol Number: JUS004 Start Date*: 2005-09-26
    Sponsor Name:University of Dundee
    Full Title: Does vitamin D improve markers of vascular health in type 2 diabetes?
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002293-54 Sponsor Protocol Number: Apex01version6 Start Date*: 2007-11-29
    Sponsor Name:University of Dundee
    Full Title: The APEX Trial: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients with Cardiac Syndrome X
    Medical condition: Patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriograms)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004565-14 Sponsor Protocol Number: 20170625 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardia...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) BG (Ongoing) ES (Ongoing) PT (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) LT (Trial now transitioned) EE (Ongoing) SK (Trial now transitioned) GR (Trial now transitioned) IT (Ongoing) RO (Ongoing) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003406-10 Sponsor Protocol Number: BC21144 Start Date*: 2007-12-13
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Ar...
    Medical condition: Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013317 Lipid metabolism disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004853-59 Sponsor Protocol Number: EX6018-4758 Start Date*: 2021-08-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation
    Disease: Version SOC Term Classification Code Term Level
    26.0 10047065 - Vascular disorders 10051615 Atherosclerotic cardiovascular disease LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.1 10022891 - Investigations 10067394 hs-CRP increased LLT
    21.0 10022891 - Investigations 10011418 CRP increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Ongoing) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Ongoing) PT (Trial now transitioned) IT (Ongoing) HU (Ongoing) CZ (Trial now transitioned) LV (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001221-14 Sponsor Protocol Number: E.G.R.A.B.I.N.S1 Start Date*: 2016-06-17
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in persons without cerebrovascular disease.
    Medical condition: This is a healthy control group which is to be compared with patients with stroke.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 23:32:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA